We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current VKTX market cap is 5.89B. The company's latest EPS is USD -0.7708 and P/E is -68.23.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -27.27M | -29.29M | -34.07M | -34.05M | -36.56M |
| Net Income | -22.53M | -24.61M | -27.36M | -22.25M | -24.94M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -32.69M | -42.66M | -55.68M | -70.36M | -100.83M |
| Net Income | -25.78M | -39.5M | -54.99M | -68.87M | -85.9M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 382.66M | 368.49M | 967.52M | 946.84M | 937.89M |
| Total Liabilities | 14.42M | 20.07M | 33.63M | 25.86M | 26.44M |
| Total Equity | 368.24M | 348.42M | 933.89M | 920.98M | 911.45M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 284.26M | 256.5M | 210.66M | 168.53M | 368.49M |
| Total Liabilities | 7.14M | 12.16M | 8.78M | 23.21M | 20.07M |
| Total Equity | 277.12M | 244.34M | 201.88M | 145.32M | 348.42M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -55.74M | -73.38M | -6.13M | -34.65M | -56.61M |
| Investing | -214.82M | -179.09M | -459.79M | -585.85M | -559.95M |
| Financing | 271.19M | 271.38M | 606.04M | 608.94M | 611.46M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -24.75M | -21.78M | -47.59M | -48.4M | -73.38M |
| Investing | 7.46M | 41.57M | 37.96M | 54.75M | -179.09M |
| Financing | 887k | 950k | 6.88M | 4.16M | 271.38M |
| Market Cap | 5.89B |
| Price to Earnings Ratio | -68.23 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 105.56 |
| Price to Book Ratio | 16.82 |
| Dividend Yield | - |
| Shares Outstanding | 111.44M |
| Average Volume (1 week) | 5.07M |
| Average Volume (1 Month) | 6.49M |
| 52 Week Change | 359.34% |
| 52 Week High | 99.3999 |
| 52 Week Low | 11.212 |
| Spread (Intraday) | 0.23 (0.44%) |
| Company Name | Viking Therapeutics Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.vikingtherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
